Moderna announced phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) began
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants.
The Phase 3 study, called the COVE (Coronavirus Efficacy) study, is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
Tags:
Source: Center for Infectious Disease Research & Policy, University of Minnesota
Credit:
